Biosimilar pegfilgrastim may offer affordable treatment options for patients in France: a budget impact analysis on the basis of clinical trial and real-world data.

Jingyan Yang Rongzhe LiuAnna GranghaudOmer Zaidi Jennifer M Stephens

Published in: Journal of medical economics (2021)

The introduction of a new pegfilgrastim biosimilar (NYVEPRIA) is potentially associated with substantial cost savings for the French healthcare system.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
randomized controlled trial
machine learning
patient reported outcomes
study protocol
chemotherapy induced
deep learning
artificial intelligence